Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

EDX Medical Group PLC (LSE:EDX): Can Diagnostic Launches Become a Scalable Business?

EDX Medical Group PLC (LSE:EDX) is being assessed against the latest company-specific information available as at 15 October 2026.

Ankur Sharma | 15 October 2026

Genedrive plc (LSE:GDR): What Could Put the Shares in Focus Next?

Genedrive plc is a healthcare-sector stock listed on AIM and included in the broader FTSE AIM All-Share market context.

Ankur Sharma | 15 October 2026

ImmuPharma plc (LSE:IMM): What Could Put the Shares in Focus Next?

ImmuPharma plc is a healthcare-sector stock listed on AIM and included in the broader FTSE AIM All-Share market context.

Ankur Sharma | 15 October 2026

IXICO PLC (LSE:IXI): Neuroscience Imaging Growth Raises the Bar for Revenue Conversion

IXICO PLC (LSE:IXI) is being assessed against the latest company-specific information available as at 15 October 2026.

Ankur Sharma | 15 October 2026

Oxford BioDynamics plc (LSE:OBD): What Could Put the Shares in Focus Next?

Oxford BioDynamics plc is a healthcare-sector stock listed on AIM and included in the broader FTSE AIM All-Share market context.

Ankur Sharma | 15 October 2026

Proteome Sciences plc (LSE:PRM): What Could Put the Shares in Focus Next?

Proteome Sciences plc is a healthcare-sector stock listed on AIM and included in the broader FTSE AIM All-Share market context.

Ankur Sharma | 15 October 2026

ValiRx PLC (LSE:VAL): Biotechnology Pipeline Progress Must Be Matched by Funding Discipline

ValiRx PLC (LSE:VAL) is being assessed against the latest company-specific information available as at 15 October 2026.

Ankur Sharma | 15 October 2026

Arecor Therapeutics PLC (LSE:AREC): Why This AIM Stock Is in Focus on 15 October 2026 and What Comes Next

Arecor Therapeutics PLC (LSE:AREC) is assessed against its operating exposure to innovative insulin formulations. The relevant investor questions concern patent protection, partners and funding.

Ankur Sharma | 15 October 2026

Bioventix Plc (LSE:BVXP): What Is Driving Attention on the AIM Market and What Comes Next?

Bioventix Plc (LSE:BVXP) trades on the London Stock Exchange’s AIM market, where corporate developments and expectations about future cash flows can strongly influence sentiment. The most relevant identified company context is specialist diagnostic antibody sales and laboratory demand. This information provides a grounded starting …

Ankur Sharma | 15 October 2026

Faron Pharmaceuticals Oy (LSE:FARN): Why This AIM Stock Is in Focus on 15 October 2026 and What Comes Next

Faron Pharmaceuticals Oy (LSE:FARN) is assessed against its operating exposure to clinical-stage immunotherapy. The relevant investor questions concern clinical readouts, financing and regulatory milestones.

Ankur Sharma | 15 October 2026
Support

Hi! How can we help you today?

Loading…